Posted by Michael Wonder on 09 Jun 2026
Health Canada authorizes Lunsumio (mosunetuzumab) for the treatment of relapsed or refractory follicular lymphoma after two or more systemic therapies
8 June 2026 - Roche Canada is pleased to announce that Health Canada has granted market authorisations for Lunsumio (mosunetuzumab for injection) and Lunsumio SC (mosunetuzumab injection) for the treatment of adult patients with relapsed or refractory follicular lymphoma (Grades 1 – 3a) who have received at least two prior systemic therapies.
The authorisations include both intravenous and subcutaneous formulations, providing healthcare providers and patients with flexible administration options.
